Literature DB >> 27035674

Patterns of oral disease in adults with chronic kidney disease treated with hemodialysis.

Suetonia C Palmer1, Marinella Ruospo2, Germaine Wong3, Jonathan C Craig3, Massimo Petruzzi4, Michele De Benedittis4, Pauline Ford5, David W Johnson6, Marcello Tonelli7, Patrizia Natale8, Valeria Saglimbene8, Fabio Pellegrini9, Eduardo Celia8, Ruben Gelfman8, Miguel R Leal8, Marietta Torok8, Paul Stroumza8, Luc Frantzen8, Anna Bednarek-Skublewska10, Jan Dulawa11, Domingo Del Castillo8, Amparo G Bernat8, Jorgen Hegbrant8, Charlotta Wollheim8, Staffan Schon8, Letizia Gargano8, Casper P Bots12, Giovanni F M Strippoli13.   

Abstract

BACKGROUND: Oral disease is a potentially treatable determinant of mortality and quality of life. No comprehensive multinational study to quantify oral disease burden and to identify candidate preventative strategies has been performed in the dialysis setting.
METHODS: The ORAL disease in hemoDialysis (ORALD) study was a prospective study in adults treated with hemodialysis in Europe (France, Hungary, Italy, Poland, Portugal and Spain) and Argentina. Oral disease was assessed using standardized WHO methods. Participants self-reported oral health practices and symptoms. Sociodemographic and clinical factors associated with oral diseases were determined and assessed within nation states.
RESULTS: Of 4726 eligible adults, 4205 (88.9%) participated. Overall, 20.6% were edentulous [95% confidence interval (CI), 19.4-21.8]. Participants had on average 22 (95% CI 21.7-22.2) decayed, missing or filled teeth, while moderate to severe periodontitis affected 40.6% (95% CI 38.9-42.3). Oral disease patterns varied markedly across countries, independent of participant demographics, comorbidity and health practices. Participants in Spain, Poland, Italy and Hungary had the highest mean adjusted odds of edentulousness (2.31, 1.90, 1.90 and 1.54, respectively), while those in Poland, Hungary, Spain and Argentina had the highest odds of ≥14 decayed, missing or filled teeth (23.2, 12.5, 8.14 and 5.23, respectively). Compared with Argentina, adjusted odds ratios for periodontitis were 58.8, 58.3, 27.7, 12.1 and 6.30 for Portugal, Italy, Hungary, France and Poland, respectively. National levels of tobacco consumption, diabetes and child poverty were associated with edentulousness within countries.
CONCLUSIONS: Oral disease in adults on hemodialysis is very common, frequently severe and highly variable among countries, with much of the variability unexplained by participant characteristics or healthcare. Given the national variation and high burden of disease, strategies to improve oral health in hemodialysis patients will require implementation at a country level rather than at the level of individuals.
© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  clinical outcomes; dental public health; epidemiology

Mesh:

Year:  2015        PMID: 27035674     DOI: 10.1093/ndt/gfv413

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  3 in total

1.  Periodontal disease and risk of mortality and kidney function decline in advanced chronic kidney disease: a nationwide population-based cohort study.

Authors:  Ying-Hsuan Tai; Jui-Tai Chen; Hsien-Cheng Kuo; Wei-Jen Chang; Mei-Yi Wu; Ying-Xiu Dai; Wan-Chi Liu; Tzeng-Ji Chen; Hsiang-Ling Wu; Yih-Giun Cherng
Journal:  Clin Oral Investig       Date:  2021-04-04       Impact factor: 3.573

2.  Oral health-related quality of life in adult patients with end-stage kidney diseases undergoing renal replacement therapy - a systematic review.

Authors:  Gerhard Schmalz; Susann Patschan; Daniel Patschan; Dirk Ziebolz
Journal:  BMC Nephrol       Date:  2020-04-29       Impact factor: 2.388

Review 3.  Oral health in patients with end-stage renal disease: A scoping review.

Authors:  Alexa Laheij; Wietse Rooijers; Lela Bidar; Lema Haidari; Aegida Neradova; Ralph de Vries; Frederik Rozema
Journal:  Clin Exp Dent Res       Date:  2021-08-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.